0

Close
 
Upcoming Allied Market Research
2023
Marine Derived Pharmaceuticals Market

Marine Derived Pharmaceuticals Market

by Type (Phenol  , Steroid  , Ether, Peptide    , Mollusk, Sponge, Tunicate  , Others), by Source (Algae  , Invertebrates,  Microorganisms), by Mode of Delivery (Anti-microbial, Anti-tumor, Anti-cardiovascular, Anti-viral, Anti-inflammatory, Others) and by End User (Hospitals    , Retail Pharmacy, Online Pharmacy  , Others): Global Opportunity Analysis and Industry Forecast, 2023-2032

LS : Pharmaceuticals
Report Code: A12469
Nov 2023 | Pages: NA
Tables: NA
Charts: NA

  • Formats*:

  • pdf

    Single User License, Five User
    License & Enterprise User License

  • xls

    Data Pack Excel License

  • ppt

    It comes with the additional cost
    of $2500.00 contact sales.
 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Marine Derived Pharmaceuticals Market

Request Now !

Marine Derived Pharmaceuticals Market Overview 2030:

Unexplored marine life has recently been the field of interest to biotechnologists and pharmaceutical industries owing to the abundance of unexplored pharmacology technology and materials that can be used for drug delivery and development. Only a few of the previously discovered marine microorganisms have proven to be potential sources of therapeutics. Some of these include sponges, sea fans, and soft corals. Recently, specific developments have been made in labs around the world in search for potential marine technologies that can aid in the treatment of diseases such as cancer and HIV/AIDS.

COVID-19 Impact Analysis

Pharmaceutical and biotech companies together with the governments around the globe are working to address the COVID-19 outbreak, from vaccines development to medicine supply chain planning.. Approximately 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as Hydroxychloroquine have witnessed a significant increase in demand for the treatment of COVID-19. Such increase in demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are experiencing a shortage of these drugs. Thus, the pharmaceutical and biotechnology industries are expected to significantly grow in the future owing to the demand for COVID-19 vaccine and the treatment medicines.. This is expected to have a substantial impact on the marine derived pharmaceuticals market.

Top Impacting Factors

  • The rise in number of cases of chronic diseases such as tuberculosis and malaria. is anticipated to drive the growth of the marine- derived pharmaceutical industry.
  • The introduction of new -age technological developments along with rise in research and developments in the field of marine exploration particularly in highly industrialized markets is anticipated to further drive the marine derived pharmaceuticals market growth.
  • The general shift of professionals toward research into unknown marine life to establish new therapeutic drugs that can be developed through marine life is expected to fuel to the growth of the marine derived drugs market.
  • Opportunities in  marine pharmacy are also expanding owing to increased awareness among less developed countries that have a high percentage of water. These include Thailand, the Maldives, Brazil and other countries.
  • High processing and development costs associated with marine- derived pharmacy products along with low purchasing parity across the globe are anticipated to hinder the marine derived pharmaceuticals market growth.
  • The complete shift of healthcare infrastructure toward eliminating the COVID-19 pandemic has resulted in product delays and cancellations for marine -derived pharmaceuticals in terms of product launches and clinical trials.

Key Market Trends

  • North America is expected to  dominate the growth of the marine drug market owing to rise in investments in marine pharmacology by both private entities and the federal government at the helm as well as  increased public awareness about leveraging unknown marine diaspora for aid in drug development.
  • Brazil and Argentina are on the verge of huge market gains as they have  the largest rainforest area in the world. To this date, the Amazon rainforest is completely inhabited and mostly unexplored which provides enormous opportunities for marine biology experts to discover new marine bioactive materials that could be used in drug manufacturing.
  • The use of chitosan along with nanotechnology shows promising results in pilot tests as far as the development of an anticancer drug delivery system is concerned (DDS)
  • Scripps Institution of Oceanography and Marine Biotechnology (SIOMB) researchers in collaboration with Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California (SSPPS) are working on clinical trials of 3RNA families for the development of advanced antiviral therapeutics.
  • A fungus derived from seagrass in the Bahamas is currently being tested. The microbe has shown promising results in destroying the vascular system of a lung tumor when used in combination with chemotherapy.
  • Researchers at a California marine lab are working at prospects of using Hercules, a robotic vessel that will be sunk into ocean- going as deep as 5000meters below sea level off the coast of California beach. The vessel takes 10 days to discover new bioactive materials and unknown marine technology that can potentially be used in the future to develop advanced therapeutics.

Key Benefits of the Report

  • This study presents the analytical depiction of the marine derived pharmaceuticals industry along with the current trends and future estimations to determine the imminent investment pockets.
  • The report presents information related to key drivers, restraints, and opportunities along with a detailed analysis of the marine derived pharmaceuticals market share.
  • The current market is quantitatively analyzed to highlight the growth scenario of the marine derived pharmaceuticals market.
  • Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
  • The report provides a detailed analysis depending on competitive intensity and the competition that will take shape in the upcoming years.

Questions Answered in the Marine Derived Pharmaceuticals Report

  • Who are the leading market players active in the marine derived pharmaceuticals market?
  • How is each segment of the market expected to grow during the forecast period?
  • What are the adoption trends for the marine- derived pharmaceuticals market in emerging economies and established economies across the world?
  • What are the current trends that will influence the market in the next few years?
  • What are the driving factors, restraints, and opportunities of the market?
  • What are the future projections that would help in taking further strategic steps?
  • What are the impacts of COVID-19 on the industry?
  • What are marine -derived pharmaceuticals?
  • What is the prediction of the marine- derived pharmaceuticals market in the future?
  • What are the current and predicted trends?

 Marine Derived Pharmaceuticals Market Report Highlights

Aspects Details
By Type
  • Phenol  
  • Steroid  
  • Ether
  • Peptide    
  • Mollusk
  • Sponge
  • Tunicate  
  • Others
By Source
  • Algae  
  • Invertebrates
  •  Microorganisms
By Mode of Delivery
  • Anti-microbial
  • Anti-tumor
  • Anti-cardiovascular
  • Anti-viral
  • Anti-inflammatory
  • Others
By End User
  • Hospitals    
  • Retail Pharmacy
  • Online Pharmacy  
  • Others
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (France, Germany, Italy, Spain, UK, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, South Africa, Saudi Arabia, Rest of LAMEA)
Key Market Players Takeda Oncology’s Millennium, Abbvie Inc, GlaxoSmithKline PLC, Marine Polymer Technologies, Inc., Sanofi S.A., Aker BioMarine AS, Abbott Laboratories, Sea Run Holdings, Inc., Bayer Innovation, Aphios Corporation
 

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

    • 3.6. COVID-19 Impact Analysis

  • CHAPTER 4: MARINE DERIVED PHARMACEUTICALS MARKET, BY TYPE

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Type

    • 4.2. Phenol  

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Steroid  

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. Ether

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

    • 4.5. Peptide    

      • 4.5.1. Key Market Trends, Growth Factors and Opportunities

      • 4.5.2. Market Size and Forecast, By Region

      • 4.5.3. Market Share Analysis, By Country

    • 4.6. Mollusk

      • 4.6.1. Key Market Trends, Growth Factors and Opportunities

      • 4.6.2. Market Size and Forecast, By Region

      • 4.6.3. Market Share Analysis, By Country

    • 4.7. Sponge

      • 4.7.1. Key Market Trends, Growth Factors and Opportunities

      • 4.7.2. Market Size and Forecast, By Region

      • 4.7.3. Market Share Analysis, By Country

    • 4.8. Tunicate  

      • 4.8.1. Key Market Trends, Growth Factors and Opportunities

      • 4.8.2. Market Size and Forecast, By Region

      • 4.8.3. Market Share Analysis, By Country

    • 4.9. Others

      • 4.9.1. Key Market Trends, Growth Factors and Opportunities

      • 4.9.2. Market Size and Forecast, By Region

      • 4.9.3. Market Share Analysis, By Country

  • CHAPTER 5: MARINE DERIVED PHARMACEUTICALS MARKET, BY SOURCE

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Source

    • 5.2. Algae  

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Invertebrates

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4.  Microorganisms

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

  • CHAPTER 6: MARINE DERIVED PHARMACEUTICALS MARKET, BY MODE OF DELIVERY

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Mode Of Delivery

    • 6.2. Anti-microbial

      • 6.2.1. Key Market Trends, Growth Factors and Opportunities

      • 6.2.2. Market Size and Forecast, By Region

      • 6.2.3. Market Share Analysis, By Country

    • 6.3. Anti-tumor

      • 6.3.1. Key Market Trends, Growth Factors and Opportunities

      • 6.3.2. Market Size and Forecast, By Region

      • 6.3.3. Market Share Analysis, By Country

    • 6.4. Anti-cardiovascular

      • 6.4.1. Key Market Trends, Growth Factors and Opportunities

      • 6.4.2. Market Size and Forecast, By Region

      • 6.4.3. Market Share Analysis, By Country

    • 6.5. Anti-viral

      • 6.5.1. Key Market Trends, Growth Factors and Opportunities

      • 6.5.2. Market Size and Forecast, By Region

      • 6.5.3. Market Share Analysis, By Country

    • 6.6. Anti-inflammatory

      • 6.6.1. Key Market Trends, Growth Factors and Opportunities

      • 6.6.2. Market Size and Forecast, By Region

      • 6.6.3. Market Share Analysis, By Country

    • 6.7. Others

      • 6.7.1. Key Market Trends, Growth Factors and Opportunities

      • 6.7.2. Market Size and Forecast, By Region

      • 6.7.3. Market Share Analysis, By Country

  • CHAPTER 7: MARINE DERIVED PHARMACEUTICALS MARKET, BY END USER

    • 7.1. Market Overview

      • 7.1.1 Market Size and Forecast, By End User

    • 7.2. Hospitals    

      • 7.2.1. Key Market Trends, Growth Factors and Opportunities

      • 7.2.2. Market Size and Forecast, By Region

      • 7.2.3. Market Share Analysis, By Country

    • 7.3. Retail Pharmacy

      • 7.3.1. Key Market Trends, Growth Factors and Opportunities

      • 7.3.2. Market Size and Forecast, By Region

      • 7.3.3. Market Share Analysis, By Country

    • 7.4. Online Pharmacy  

      • 7.4.1. Key Market Trends, Growth Factors and Opportunities

      • 7.4.2. Market Size and Forecast, By Region

      • 7.4.3. Market Share Analysis, By Country

    • 7.5. Others

      • 7.5.1. Key Market Trends, Growth Factors and Opportunities

      • 7.5.2. Market Size and Forecast, By Region

      • 7.5.3. Market Share Analysis, By Country

  • CHAPTER 8: MARINE DERIVED PHARMACEUTICALS MARKET, BY REGION

    • 8.1. Market Overview

      • 8.1.1 Market Size and Forecast, By Region

    • 8.2. North America

      • 8.2.1. Key Market Trends and Opportunities

      • 8.2.2. Market Size and Forecast, By Type

      • 8.2.3. Market Size and Forecast, By Source

      • 8.2.4. Market Size and Forecast, By Mode Of Delivery

      • 8.2.5. Market Size and Forecast, By End User

      • 8.2.6. Market Size and Forecast, By Country

      • 8.2.7. U.S. Marine Derived Pharmaceuticals Market

        • 8.2.7.1. Market Size and Forecast, By Type
        • 8.2.7.2. Market Size and Forecast, By Source
        • 8.2.7.3. Market Size and Forecast, By Mode Of Delivery
        • 8.2.7.4. Market Size and Forecast, By End User

      • 8.2.8. Canada Marine Derived Pharmaceuticals Market

        • 8.2.8.1. Market Size and Forecast, By Type
        • 8.2.8.2. Market Size and Forecast, By Source
        • 8.2.8.3. Market Size and Forecast, By Mode Of Delivery
        • 8.2.8.4. Market Size and Forecast, By End User

      • 8.2.9. Mexico Marine Derived Pharmaceuticals Market

        • 8.2.9.1. Market Size and Forecast, By Type
        • 8.2.9.2. Market Size and Forecast, By Source
        • 8.2.9.3. Market Size and Forecast, By Mode Of Delivery
        • 8.2.9.4. Market Size and Forecast, By End User

    • 8.3. Europe

      • 8.3.1. Key Market Trends and Opportunities

      • 8.3.2. Market Size and Forecast, By Type

      • 8.3.3. Market Size and Forecast, By Source

      • 8.3.4. Market Size and Forecast, By Mode Of Delivery

      • 8.3.5. Market Size and Forecast, By End User

      • 8.3.6. Market Size and Forecast, By Country

      • 8.3.7. France Marine Derived Pharmaceuticals Market

        • 8.3.7.1. Market Size and Forecast, By Type
        • 8.3.7.2. Market Size and Forecast, By Source
        • 8.3.7.3. Market Size and Forecast, By Mode Of Delivery
        • 8.3.7.4. Market Size and Forecast, By End User

      • 8.3.8. Germany Marine Derived Pharmaceuticals Market

        • 8.3.8.1. Market Size and Forecast, By Type
        • 8.3.8.2. Market Size and Forecast, By Source
        • 8.3.8.3. Market Size and Forecast, By Mode Of Delivery
        • 8.3.8.4. Market Size and Forecast, By End User

      • 8.3.9. Italy Marine Derived Pharmaceuticals Market

        • 8.3.9.1. Market Size and Forecast, By Type
        • 8.3.9.2. Market Size and Forecast, By Source
        • 8.3.9.3. Market Size and Forecast, By Mode Of Delivery
        • 8.3.9.4. Market Size and Forecast, By End User

      • 8.3.10. Spain Marine Derived Pharmaceuticals Market

        • 8.3.10.1. Market Size and Forecast, By Type
        • 8.3.10.2. Market Size and Forecast, By Source
        • 8.3.10.3. Market Size and Forecast, By Mode Of Delivery
        • 8.3.10.4. Market Size and Forecast, By End User

      • 8.3.11. UK Marine Derived Pharmaceuticals Market

        • 8.3.11.1. Market Size and Forecast, By Type
        • 8.3.11.2. Market Size and Forecast, By Source
        • 8.3.11.3. Market Size and Forecast, By Mode Of Delivery
        • 8.3.11.4. Market Size and Forecast, By End User

      • 8.3.12. Russia Marine Derived Pharmaceuticals Market

        • 8.3.12.1. Market Size and Forecast, By Type
        • 8.3.12.2. Market Size and Forecast, By Source
        • 8.3.12.3. Market Size and Forecast, By Mode Of Delivery
        • 8.3.12.4. Market Size and Forecast, By End User

      • 8.3.13. Rest Of Europe Marine Derived Pharmaceuticals Market

        • 8.3.13.1. Market Size and Forecast, By Type
        • 8.3.13.2. Market Size and Forecast, By Source
        • 8.3.13.3. Market Size and Forecast, By Mode Of Delivery
        • 8.3.13.4. Market Size and Forecast, By End User

    • 8.4. Asia-Pacific

      • 8.4.1. Key Market Trends and Opportunities

      • 8.4.2. Market Size and Forecast, By Type

      • 8.4.3. Market Size and Forecast, By Source

      • 8.4.4. Market Size and Forecast, By Mode Of Delivery

      • 8.4.5. Market Size and Forecast, By End User

      • 8.4.6. Market Size and Forecast, By Country

      • 8.4.7. China Marine Derived Pharmaceuticals Market

        • 8.4.7.1. Market Size and Forecast, By Type
        • 8.4.7.2. Market Size and Forecast, By Source
        • 8.4.7.3. Market Size and Forecast, By Mode Of Delivery
        • 8.4.7.4. Market Size and Forecast, By End User

      • 8.4.8. Japan Marine Derived Pharmaceuticals Market

        • 8.4.8.1. Market Size and Forecast, By Type
        • 8.4.8.2. Market Size and Forecast, By Source
        • 8.4.8.3. Market Size and Forecast, By Mode Of Delivery
        • 8.4.8.4. Market Size and Forecast, By End User

      • 8.4.9. India Marine Derived Pharmaceuticals Market

        • 8.4.9.1. Market Size and Forecast, By Type
        • 8.4.9.2. Market Size and Forecast, By Source
        • 8.4.9.3. Market Size and Forecast, By Mode Of Delivery
        • 8.4.9.4. Market Size and Forecast, By End User

      • 8.4.10. South Korea Marine Derived Pharmaceuticals Market

        • 8.4.10.1. Market Size and Forecast, By Type
        • 8.4.10.2. Market Size and Forecast, By Source
        • 8.4.10.3. Market Size and Forecast, By Mode Of Delivery
        • 8.4.10.4. Market Size and Forecast, By End User

      • 8.4.11. Australia Marine Derived Pharmaceuticals Market

        • 8.4.11.1. Market Size and Forecast, By Type
        • 8.4.11.2. Market Size and Forecast, By Source
        • 8.4.11.3. Market Size and Forecast, By Mode Of Delivery
        • 8.4.11.4. Market Size and Forecast, By End User

      • 8.4.12. Thailand Marine Derived Pharmaceuticals Market

        • 8.4.12.1. Market Size and Forecast, By Type
        • 8.4.12.2. Market Size and Forecast, By Source
        • 8.4.12.3. Market Size and Forecast, By Mode Of Delivery
        • 8.4.12.4. Market Size and Forecast, By End User

      • 8.4.13. Malaysia Marine Derived Pharmaceuticals Market

        • 8.4.13.1. Market Size and Forecast, By Type
        • 8.4.13.2. Market Size and Forecast, By Source
        • 8.4.13.3. Market Size and Forecast, By Mode Of Delivery
        • 8.4.13.4. Market Size and Forecast, By End User

      • 8.4.14. Indonesia Marine Derived Pharmaceuticals Market

        • 8.4.14.1. Market Size and Forecast, By Type
        • 8.4.14.2. Market Size and Forecast, By Source
        • 8.4.14.3. Market Size and Forecast, By Mode Of Delivery
        • 8.4.14.4. Market Size and Forecast, By End User

      • 8.4.15. Rest of Asia Pacific Marine Derived Pharmaceuticals Market

        • 8.4.15.1. Market Size and Forecast, By Type
        • 8.4.15.2. Market Size and Forecast, By Source
        • 8.4.15.3. Market Size and Forecast, By Mode Of Delivery
        • 8.4.15.4. Market Size and Forecast, By End User

    • 8.5. LAMEA

      • 8.5.1. Key Market Trends and Opportunities

      • 8.5.2. Market Size and Forecast, By Type

      • 8.5.3. Market Size and Forecast, By Source

      • 8.5.4. Market Size and Forecast, By Mode Of Delivery

      • 8.5.5. Market Size and Forecast, By End User

      • 8.5.6. Market Size and Forecast, By Country

      • 8.5.7. Brazil Marine Derived Pharmaceuticals Market

        • 8.5.7.1. Market Size and Forecast, By Type
        • 8.5.7.2. Market Size and Forecast, By Source
        • 8.5.7.3. Market Size and Forecast, By Mode Of Delivery
        • 8.5.7.4. Market Size and Forecast, By End User

      • 8.5.8. South Africa Marine Derived Pharmaceuticals Market

        • 8.5.8.1. Market Size and Forecast, By Type
        • 8.5.8.2. Market Size and Forecast, By Source
        • 8.5.8.3. Market Size and Forecast, By Mode Of Delivery
        • 8.5.8.4. Market Size and Forecast, By End User

      • 8.5.9. Saudi Arabia Marine Derived Pharmaceuticals Market

        • 8.5.9.1. Market Size and Forecast, By Type
        • 8.5.9.2. Market Size and Forecast, By Source
        • 8.5.9.3. Market Size and Forecast, By Mode Of Delivery
        • 8.5.9.4. Market Size and Forecast, By End User

      • 8.5.10. UAE Marine Derived Pharmaceuticals Market

        • 8.5.10.1. Market Size and Forecast, By Type
        • 8.5.10.2. Market Size and Forecast, By Source
        • 8.5.10.3. Market Size and Forecast, By Mode Of Delivery
        • 8.5.10.4. Market Size and Forecast, By End User

      • 8.5.11. Argentina Marine Derived Pharmaceuticals Market

        • 8.5.11.1. Market Size and Forecast, By Type
        • 8.5.11.2. Market Size and Forecast, By Source
        • 8.5.11.3. Market Size and Forecast, By Mode Of Delivery
        • 8.5.11.4. Market Size and Forecast, By End User

      • 8.5.12. Rest of LAMEA Marine Derived Pharmaceuticals Market

        • 8.5.12.1. Market Size and Forecast, By Type
        • 8.5.12.2. Market Size and Forecast, By Source
        • 8.5.12.3. Market Size and Forecast, By Mode Of Delivery
        • 8.5.12.4. Market Size and Forecast, By End User

  • CHAPTER 9: COMPETITIVE LANDSCAPE

    • 9.1. Introduction

    • 9.2. Top Winning Strategies

    • 9.3. Product Mapping Of Top 10 Player

    • 9.4. Competitive Dashboard

    • 9.5. Competitive Heatmap

    • 9.6. Top Player Positioning,2022

  • CHAPTER 10: COMPANY PROFILES

    • 10.1. Abbott Laboratories

      • 10.1.1. Company Overview

      • 10.1.2. Key Executives

      • 10.1.3. Company Snapshot

      • 10.1.4. Operating Business Segments

      • 10.1.5. Product Portfolio

      • 10.1.6. Business Performance

      • 10.1.7. Key Strategic Moves and Developments

    • 10.2. Bayer Innovation

      • 10.2.1. Company Overview

      • 10.2.2. Key Executives

      • 10.2.3. Company Snapshot

      • 10.2.4. Operating Business Segments

      • 10.2.5. Product Portfolio

      • 10.2.6. Business Performance

      • 10.2.7. Key Strategic Moves and Developments

    • 10.3. Marine Polymer Technologies, Inc.

      • 10.3.1. Company Overview

      • 10.3.2. Key Executives

      • 10.3.3. Company Snapshot

      • 10.3.4. Operating Business Segments

      • 10.3.5. Product Portfolio

      • 10.3.6. Business Performance

      • 10.3.7. Key Strategic Moves and Developments

    • 10.4. Takeda Oncology’s Millennium

      • 10.4.1. Company Overview

      • 10.4.2. Key Executives

      • 10.4.3. Company Snapshot

      • 10.4.4. Operating Business Segments

      • 10.4.5. Product Portfolio

      • 10.4.6. Business Performance

      • 10.4.7. Key Strategic Moves and Developments

    • 10.5. GlaxoSmithKline PLC

      • 10.5.1. Company Overview

      • 10.5.2. Key Executives

      • 10.5.3. Company Snapshot

      • 10.5.4. Operating Business Segments

      • 10.5.5. Product Portfolio

      • 10.5.6. Business Performance

      • 10.5.7. Key Strategic Moves and Developments

    • 10.6. Abbvie Inc

      • 10.6.1. Company Overview

      • 10.6.2. Key Executives

      • 10.6.3. Company Snapshot

      • 10.6.4. Operating Business Segments

      • 10.6.5. Product Portfolio

      • 10.6.6. Business Performance

      • 10.6.7. Key Strategic Moves and Developments

    • 10.7. Aker BioMarine AS

      • 10.7.1. Company Overview

      • 10.7.2. Key Executives

      • 10.7.3. Company Snapshot

      • 10.7.4. Operating Business Segments

      • 10.7.5. Product Portfolio

      • 10.7.6. Business Performance

      • 10.7.7. Key Strategic Moves and Developments

    • 10.8. Sea Run Holdings, Inc.

      • 10.8.1. Company Overview

      • 10.8.2. Key Executives

      • 10.8.3. Company Snapshot

      • 10.8.4. Operating Business Segments

      • 10.8.5. Product Portfolio

      • 10.8.6. Business Performance

      • 10.8.7. Key Strategic Moves and Developments

    • 10.9. Aphios Corporation

      • 10.9.1. Company Overview

      • 10.9.2. Key Executives

      • 10.9.3. Company Snapshot

      • 10.9.4. Operating Business Segments

      • 10.9.5. Product Portfolio

      • 10.9.6. Business Performance

      • 10.9.7. Key Strategic Moves and Developments

    • 10.10. Sanofi S.A.

      • 10.10.1. Company Overview

      • 10.10.2. Key Executives

      • 10.10.3. Company Snapshot

      • 10.10.4. Operating Business Segments

      • 10.10.5. Product Portfolio

      • 10.10.6. Business Performance

      • 10.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL MARINE DERIVED PHARMACEUTICALS MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 2. GLOBAL MARINE DERIVED PHARMACEUTICALS MARKET FOR PHENOL  , BY REGION, 2022-2032 ($MILLION)
  • TABLE 3. GLOBAL MARINE DERIVED PHARMACEUTICALS MARKET FOR STEROID  , BY REGION, 2022-2032 ($MILLION)
  • TABLE 4. GLOBAL MARINE DERIVED PHARMACEUTICALS MARKET FOR ETHER, BY REGION, 2022-2032 ($MILLION)
  • TABLE 5. GLOBAL MARINE DERIVED PHARMACEUTICALS MARKET FOR PEPTIDE    , BY REGION, 2022-2032 ($MILLION)
  • TABLE 6. GLOBAL MARINE DERIVED PHARMACEUTICALS MARKET FOR MOLLUSK, BY REGION, 2022-2032 ($MILLION)
  • TABLE 7. GLOBAL MARINE DERIVED PHARMACEUTICALS MARKET FOR SPONGE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 8. GLOBAL MARINE DERIVED PHARMACEUTICALS MARKET FOR TUNICATE  , BY REGION, 2022-2032 ($MILLION)
  • TABLE 9. GLOBAL MARINE DERIVED PHARMACEUTICALS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. GLOBAL MARINE DERIVED PHARMACEUTICALS MARKET, BY SOURCE, 2022-2032 ($MILLION)
  • TABLE 11. GLOBAL MARINE DERIVED PHARMACEUTICALS MARKET FOR ALGAE  , BY REGION, 2022-2032 ($MILLION)
  • TABLE 12. GLOBAL MARINE DERIVED PHARMACEUTICALS MARKET FOR INVERTEBRATES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. GLOBAL MARINE DERIVED PHARMACEUTICALS MARKET FOR  MICROORGANISMS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 14. GLOBAL MARINE DERIVED PHARMACEUTICALS MARKET, BY MODE OF DELIVERY, 2022-2032 ($MILLION)
  • TABLE 15. GLOBAL MARINE DERIVED PHARMACEUTICALS MARKET FOR ANTI-MICROBIAL, BY REGION, 2022-2032 ($MILLION)
  • TABLE 16. GLOBAL MARINE DERIVED PHARMACEUTICALS MARKET FOR ANTI-TUMOR, BY REGION, 2022-2032 ($MILLION)
  • TABLE 17. GLOBAL MARINE DERIVED PHARMACEUTICALS MARKET FOR ANTI-CARDIOVASCULAR, BY REGION, 2022-2032 ($MILLION)
  • TABLE 18. GLOBAL MARINE DERIVED PHARMACEUTICALS MARKET FOR ANTI-VIRAL, BY REGION, 2022-2032 ($MILLION)
  • TABLE 19. GLOBAL MARINE DERIVED PHARMACEUTICALS MARKET FOR ANTI-INFLAMMATORY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 20. GLOBAL MARINE DERIVED PHARMACEUTICALS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 21. GLOBAL MARINE DERIVED PHARMACEUTICALS MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 22. GLOBAL MARINE DERIVED PHARMACEUTICALS MARKET FOR HOSPITALS    , BY REGION, 2022-2032 ($MILLION)
  • TABLE 23. GLOBAL MARINE DERIVED PHARMACEUTICALS MARKET FOR RETAIL PHARMACY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 24. GLOBAL MARINE DERIVED PHARMACEUTICALS MARKET FOR ONLINE PHARMACY  , BY REGION, 2022-2032 ($MILLION)
  • TABLE 25. GLOBAL MARINE DERIVED PHARMACEUTICALS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 26. GLOBAL MARINE DERIVED PHARMACEUTICALS MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 27. NORTH AMERICA MARINE DERIVED PHARMACEUTICALS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 28. NORTH AMERICA MARINE DERIVED PHARMACEUTICALS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 29. NORTH AMERICA MARINE DERIVED PHARMACEUTICALS, BY SOURCE, 2022-2032 ($MILLION)
  • TABLE 30. NORTH AMERICA MARINE DERIVED PHARMACEUTICALS, BY MODE OF DELIVERY, 2022-2032 ($MILLION)
  • TABLE 31. NORTH AMERICA MARINE DERIVED PHARMACEUTICALS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 32. U.S. MARINE DERIVED PHARMACEUTICALS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 33. U.S. MARINE DERIVED PHARMACEUTICALS, BY SOURCE, 2022-2032 ($MILLION)
  • TABLE 34. U.S. MARINE DERIVED PHARMACEUTICALS, BY MODE OF DELIVERY, 2022-2032 ($MILLION)
  • TABLE 35. U.S. MARINE DERIVED PHARMACEUTICALS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 36. CANADA MARINE DERIVED PHARMACEUTICALS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 37. CANADA MARINE DERIVED PHARMACEUTICALS, BY SOURCE, 2022-2032 ($MILLION)
  • TABLE 38. CANADA MARINE DERIVED PHARMACEUTICALS, BY MODE OF DELIVERY, 2022-2032 ($MILLION)
  • TABLE 39. CANADA MARINE DERIVED PHARMACEUTICALS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 40. MEXICO MARINE DERIVED PHARMACEUTICALS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 41. MEXICO MARINE DERIVED PHARMACEUTICALS, BY SOURCE, 2022-2032 ($MILLION)
  • TABLE 42. MEXICO MARINE DERIVED PHARMACEUTICALS, BY MODE OF DELIVERY, 2022-2032 ($MILLION)
  • TABLE 43. MEXICO MARINE DERIVED PHARMACEUTICALS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 44. EUROPE MARINE DERIVED PHARMACEUTICALS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 45. EUROPE MARINE DERIVED PHARMACEUTICALS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 46. EUROPE MARINE DERIVED PHARMACEUTICALS, BY SOURCE, 2022-2032 ($MILLION)
  • TABLE 47. EUROPE MARINE DERIVED PHARMACEUTICALS, BY MODE OF DELIVERY, 2022-2032 ($MILLION)
  • TABLE 48. EUROPE MARINE DERIVED PHARMACEUTICALS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 49. FRANCE MARINE DERIVED PHARMACEUTICALS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 50. FRANCE MARINE DERIVED PHARMACEUTICALS, BY SOURCE, 2022-2032 ($MILLION)
  • TABLE 51. FRANCE MARINE DERIVED PHARMACEUTICALS, BY MODE OF DELIVERY, 2022-2032 ($MILLION)
  • TABLE 52. FRANCE MARINE DERIVED PHARMACEUTICALS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 53. GERMANY MARINE DERIVED PHARMACEUTICALS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 54. GERMANY MARINE DERIVED PHARMACEUTICALS, BY SOURCE, 2022-2032 ($MILLION)
  • TABLE 55. GERMANY MARINE DERIVED PHARMACEUTICALS, BY MODE OF DELIVERY, 2022-2032 ($MILLION)
  • TABLE 56. GERMANY MARINE DERIVED PHARMACEUTICALS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 57. ITALY MARINE DERIVED PHARMACEUTICALS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 58. ITALY MARINE DERIVED PHARMACEUTICALS, BY SOURCE, 2022-2032 ($MILLION)
  • TABLE 59. ITALY MARINE DERIVED PHARMACEUTICALS, BY MODE OF DELIVERY, 2022-2032 ($MILLION)
  • TABLE 60. ITALY MARINE DERIVED PHARMACEUTICALS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 61. SPAIN MARINE DERIVED PHARMACEUTICALS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 62. SPAIN MARINE DERIVED PHARMACEUTICALS, BY SOURCE, 2022-2032 ($MILLION)
  • TABLE 63. SPAIN MARINE DERIVED PHARMACEUTICALS, BY MODE OF DELIVERY, 2022-2032 ($MILLION)
  • TABLE 64. SPAIN MARINE DERIVED PHARMACEUTICALS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 65. UK MARINE DERIVED PHARMACEUTICALS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 66. UK MARINE DERIVED PHARMACEUTICALS, BY SOURCE, 2022-2032 ($MILLION)
  • TABLE 67. UK MARINE DERIVED PHARMACEUTICALS, BY MODE OF DELIVERY, 2022-2032 ($MILLION)
  • TABLE 68. UK MARINE DERIVED PHARMACEUTICALS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 69. RUSSIA MARINE DERIVED PHARMACEUTICALS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 70. RUSSIA MARINE DERIVED PHARMACEUTICALS, BY SOURCE, 2022-2032 ($MILLION)
  • TABLE 71. RUSSIA MARINE DERIVED PHARMACEUTICALS, BY MODE OF DELIVERY, 2022-2032 ($MILLION)
  • TABLE 72. RUSSIA MARINE DERIVED PHARMACEUTICALS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 73. REST OF EUROPE MARINE DERIVED PHARMACEUTICALS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 74. REST OF EUROPE MARINE DERIVED PHARMACEUTICALS, BY SOURCE, 2022-2032 ($MILLION)
  • TABLE 75. REST OF EUROPE MARINE DERIVED PHARMACEUTICALS, BY MODE OF DELIVERY, 2022-2032 ($MILLION)
  • TABLE 76. REST OF EUROPE MARINE DERIVED PHARMACEUTICALS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 77. ASIA-PACIFIC MARINE DERIVED PHARMACEUTICALS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 78. ASIA-PACIFIC MARINE DERIVED PHARMACEUTICALS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 79. ASIA-PACIFIC MARINE DERIVED PHARMACEUTICALS, BY SOURCE, 2022-2032 ($MILLION)
  • TABLE 80. ASIA-PACIFIC MARINE DERIVED PHARMACEUTICALS, BY MODE OF DELIVERY, 2022-2032 ($MILLION)
  • TABLE 81. ASIA-PACIFIC MARINE DERIVED PHARMACEUTICALS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 82. CHINA MARINE DERIVED PHARMACEUTICALS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 83. CHINA MARINE DERIVED PHARMACEUTICALS, BY SOURCE, 2022-2032 ($MILLION)
  • TABLE 84. CHINA MARINE DERIVED PHARMACEUTICALS, BY MODE OF DELIVERY, 2022-2032 ($MILLION)
  • TABLE 85. CHINA MARINE DERIVED PHARMACEUTICALS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 86. JAPAN MARINE DERIVED PHARMACEUTICALS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 87. JAPAN MARINE DERIVED PHARMACEUTICALS, BY SOURCE, 2022-2032 ($MILLION)
  • TABLE 88. JAPAN MARINE DERIVED PHARMACEUTICALS, BY MODE OF DELIVERY, 2022-2032 ($MILLION)
  • TABLE 89. JAPAN MARINE DERIVED PHARMACEUTICALS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 90. INDIA MARINE DERIVED PHARMACEUTICALS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 91. INDIA MARINE DERIVED PHARMACEUTICALS, BY SOURCE, 2022-2032 ($MILLION)
  • TABLE 92. INDIA MARINE DERIVED PHARMACEUTICALS, BY MODE OF DELIVERY, 2022-2032 ($MILLION)
  • TABLE 93. INDIA MARINE DERIVED PHARMACEUTICALS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 94. SOUTH KOREA MARINE DERIVED PHARMACEUTICALS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 95. SOUTH KOREA MARINE DERIVED PHARMACEUTICALS, BY SOURCE, 2022-2032 ($MILLION)
  • TABLE 96. SOUTH KOREA MARINE DERIVED PHARMACEUTICALS, BY MODE OF DELIVERY, 2022-2032 ($MILLION)
  • TABLE 97. SOUTH KOREA MARINE DERIVED PHARMACEUTICALS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 98. AUSTRALIA MARINE DERIVED PHARMACEUTICALS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 99. AUSTRALIA MARINE DERIVED PHARMACEUTICALS, BY SOURCE, 2022-2032 ($MILLION)
  • TABLE 100. AUSTRALIA MARINE DERIVED PHARMACEUTICALS, BY MODE OF DELIVERY, 2022-2032 ($MILLION)
  • TABLE 101. AUSTRALIA MARINE DERIVED PHARMACEUTICALS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 102. THAILAND MARINE DERIVED PHARMACEUTICALS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 103. THAILAND MARINE DERIVED PHARMACEUTICALS, BY SOURCE, 2022-2032 ($MILLION)
  • TABLE 104. THAILAND MARINE DERIVED PHARMACEUTICALS, BY MODE OF DELIVERY, 2022-2032 ($MILLION)
  • TABLE 105. THAILAND MARINE DERIVED PHARMACEUTICALS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 106. MALAYSIA MARINE DERIVED PHARMACEUTICALS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 107. MALAYSIA MARINE DERIVED PHARMACEUTICALS, BY SOURCE, 2022-2032 ($MILLION)
  • TABLE 108. MALAYSIA MARINE DERIVED PHARMACEUTICALS, BY MODE OF DELIVERY, 2022-2032 ($MILLION)
  • TABLE 109. MALAYSIA MARINE DERIVED PHARMACEUTICALS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 110. INDONESIA MARINE DERIVED PHARMACEUTICALS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 111. INDONESIA MARINE DERIVED PHARMACEUTICALS, BY SOURCE, 2022-2032 ($MILLION)
  • TABLE 112. INDONESIA MARINE DERIVED PHARMACEUTICALS, BY MODE OF DELIVERY, 2022-2032 ($MILLION)
  • TABLE 113. INDONESIA MARINE DERIVED PHARMACEUTICALS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 114. REST OF ASIA PACIFIC MARINE DERIVED PHARMACEUTICALS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 115. REST OF ASIA PACIFIC MARINE DERIVED PHARMACEUTICALS, BY SOURCE, 2022-2032 ($MILLION)
  • TABLE 116. REST OF ASIA PACIFIC MARINE DERIVED PHARMACEUTICALS, BY MODE OF DELIVERY, 2022-2032 ($MILLION)
  • TABLE 117. REST OF ASIA PACIFIC MARINE DERIVED PHARMACEUTICALS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 118. LAMEA MARINE DERIVED PHARMACEUTICALS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 119. LAMEA MARINE DERIVED PHARMACEUTICALS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 120. LAMEA MARINE DERIVED PHARMACEUTICALS, BY SOURCE, 2022-2032 ($MILLION)
  • TABLE 121. LAMEA MARINE DERIVED PHARMACEUTICALS, BY MODE OF DELIVERY, 2022-2032 ($MILLION)
  • TABLE 122. LAMEA MARINE DERIVED PHARMACEUTICALS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 123. BRAZIL MARINE DERIVED PHARMACEUTICALS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 124. BRAZIL MARINE DERIVED PHARMACEUTICALS, BY SOURCE, 2022-2032 ($MILLION)
  • TABLE 125. BRAZIL MARINE DERIVED PHARMACEUTICALS, BY MODE OF DELIVERY, 2022-2032 ($MILLION)
  • TABLE 126. BRAZIL MARINE DERIVED PHARMACEUTICALS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 127. SOUTH AFRICA MARINE DERIVED PHARMACEUTICALS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 128. SOUTH AFRICA MARINE DERIVED PHARMACEUTICALS, BY SOURCE, 2022-2032 ($MILLION)
  • TABLE 129. SOUTH AFRICA MARINE DERIVED PHARMACEUTICALS, BY MODE OF DELIVERY, 2022-2032 ($MILLION)
  • TABLE 130. SOUTH AFRICA MARINE DERIVED PHARMACEUTICALS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 131. SAUDI ARABIA MARINE DERIVED PHARMACEUTICALS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 132. SAUDI ARABIA MARINE DERIVED PHARMACEUTICALS, BY SOURCE, 2022-2032 ($MILLION)
  • TABLE 133. SAUDI ARABIA MARINE DERIVED PHARMACEUTICALS, BY MODE OF DELIVERY, 2022-2032 ($MILLION)
  • TABLE 134. SAUDI ARABIA MARINE DERIVED PHARMACEUTICALS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 135. UAE MARINE DERIVED PHARMACEUTICALS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 136. UAE MARINE DERIVED PHARMACEUTICALS, BY SOURCE, 2022-2032 ($MILLION)
  • TABLE 137. UAE MARINE DERIVED PHARMACEUTICALS, BY MODE OF DELIVERY, 2022-2032 ($MILLION)
  • TABLE 138. UAE MARINE DERIVED PHARMACEUTICALS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 139. ARGENTINA MARINE DERIVED PHARMACEUTICALS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 140. ARGENTINA MARINE DERIVED PHARMACEUTICALS, BY SOURCE, 2022-2032 ($MILLION)
  • TABLE 141. ARGENTINA MARINE DERIVED PHARMACEUTICALS, BY MODE OF DELIVERY, 2022-2032 ($MILLION)
  • TABLE 142. ARGENTINA MARINE DERIVED PHARMACEUTICALS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 143. REST OF LAMEA MARINE DERIVED PHARMACEUTICALS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 144. REST OF LAMEA MARINE DERIVED PHARMACEUTICALS, BY SOURCE, 2022-2032 ($MILLION)
  • TABLE 145. REST OF LAMEA MARINE DERIVED PHARMACEUTICALS, BY MODE OF DELIVERY, 2022-2032 ($MILLION)
  • TABLE 146. REST OF LAMEA MARINE DERIVED PHARMACEUTICALS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 147. ABBOTT LABORATORIES: KEY EXECUTIVES
  • TABLE 148. ABBOTT LABORATORIES: COMPANY SNAPSHOT
  • TABLE 149. ABBOTT LABORATORIES: OPERATING SEGMENTS
  • TABLE 150. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
  • TABLE 151. ABBOTT LABORATORIES: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 152. BAYER INNOVATION: KEY EXECUTIVES
  • TABLE 153. BAYER INNOVATION: COMPANY SNAPSHOT
  • TABLE 154. BAYER INNOVATION: OPERATING SEGMENTS
  • TABLE 155. BAYER INNOVATION: PRODUCT PORTFOLIO
  • TABLE 156. BAYER INNOVATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 157. MARINE POLYMER TECHNOLOGIES, INC.: KEY EXECUTIVES
  • TABLE 158. MARINE POLYMER TECHNOLOGIES, INC.: COMPANY SNAPSHOT
  • TABLE 159. MARINE POLYMER TECHNOLOGIES, INC.: OPERATING SEGMENTS
  • TABLE 160. MARINE POLYMER TECHNOLOGIES, INC.: PRODUCT PORTFOLIO
  • TABLE 161. MARINE POLYMER TECHNOLOGIES, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 162. TAKEDA ONCOLOGY’S MILLENNIUM: KEY EXECUTIVES
  • TABLE 163. TAKEDA ONCOLOGY’S MILLENNIUM: COMPANY SNAPSHOT
  • TABLE 164. TAKEDA ONCOLOGY’S MILLENNIUM: OPERATING SEGMENTS
  • TABLE 165. TAKEDA ONCOLOGY’S MILLENNIUM: PRODUCT PORTFOLIO
  • TABLE 166. TAKEDA ONCOLOGY’S MILLENNIUM: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 167. GLAXOSMITHKLINE PLC: KEY EXECUTIVES
  • TABLE 168. GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
  • TABLE 169. GLAXOSMITHKLINE PLC: OPERATING SEGMENTS
  • TABLE 170. GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
  • TABLE 171. GLAXOSMITHKLINE PLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 172. ABBVIE INC: KEY EXECUTIVES
  • TABLE 173. ABBVIE INC: COMPANY SNAPSHOT
  • TABLE 174. ABBVIE INC: OPERATING SEGMENTS
  • TABLE 175. ABBVIE INC: PRODUCT PORTFOLIO
  • TABLE 176. ABBVIE INC: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 177. AKER BIOMARINE AS: KEY EXECUTIVES
  • TABLE 178. AKER BIOMARINE AS: COMPANY SNAPSHOT
  • TABLE 179. AKER BIOMARINE AS: OPERATING SEGMENTS
  • TABLE 180. AKER BIOMARINE AS: PRODUCT PORTFOLIO
  • TABLE 181. AKER BIOMARINE AS: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 182. SEA RUN HOLDINGS, INC.: KEY EXECUTIVES
  • TABLE 183. SEA RUN HOLDINGS, INC.: COMPANY SNAPSHOT
  • TABLE 184. SEA RUN HOLDINGS, INC.: OPERATING SEGMENTS
  • TABLE 185. SEA RUN HOLDINGS, INC.: PRODUCT PORTFOLIO
  • TABLE 186. SEA RUN HOLDINGS, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 187. APHIOS CORPORATION: KEY EXECUTIVES
  • TABLE 188. APHIOS CORPORATION: COMPANY SNAPSHOT
  • TABLE 189. APHIOS CORPORATION: OPERATING SEGMENTS
  • TABLE 190. APHIOS CORPORATION: PRODUCT PORTFOLIO
  • TABLE 191. APHIOS CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 192. SANOFI S.A.: KEY EXECUTIVES
  • TABLE 193. SANOFI S.A.: COMPANY SNAPSHOT
  • TABLE 194. SANOFI S.A.: OPERATING SEGMENTS
  • TABLE 195. SANOFI S.A.: PRODUCT PORTFOLIO
  • TABLE 196. SANOFI S.A.: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL MARINE DERIVED PHARMACEUTICALS MARKET SEGMENTATION
  • FIGURE 2. GLOBAL MARINE DERIVED PHARMACEUTICALS MARKET
  • FIGURE 3. SEGMENTATION MARINE DERIVED PHARMACEUTICALS MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN MARINE DERIVED PHARMACEUTICALS MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALMARINE DERIVED PHARMACEUTICALS MARKET
  • FIGURE 11. MARINE DERIVED PHARMACEUTICALS MARKET SEGMENTATION, BY BY TYPE
  • FIGURE 12. MARINE DERIVED PHARMACEUTICALS MARKET FOR PHENOL  , BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 13. MARINE DERIVED PHARMACEUTICALS MARKET FOR STEROID  , BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 14. MARINE DERIVED PHARMACEUTICALS MARKET FOR ETHER, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 15. MARINE DERIVED PHARMACEUTICALS MARKET FOR PEPTIDE    , BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 16. MARINE DERIVED PHARMACEUTICALS MARKET FOR MOLLUSK, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 17. MARINE DERIVED PHARMACEUTICALS MARKET FOR SPONGE, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 18. MARINE DERIVED PHARMACEUTICALS MARKET FOR TUNICATE  , BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 19. MARINE DERIVED PHARMACEUTICALS MARKET FOR OTHERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 20. MARINE DERIVED PHARMACEUTICALS MARKET SEGMENTATION, BY BY SOURCE
  • FIGURE 21. MARINE DERIVED PHARMACEUTICALS MARKET FOR ALGAE  , BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 22. MARINE DERIVED PHARMACEUTICALS MARKET FOR INVERTEBRATES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 23. MARINE DERIVED PHARMACEUTICALS MARKET FOR  MICROORGANISMS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 24. MARINE DERIVED PHARMACEUTICALS MARKET SEGMENTATION, BY BY MODE OF DELIVERY
  • FIGURE 25. MARINE DERIVED PHARMACEUTICALS MARKET FOR ANTI-MICROBIAL, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 26. MARINE DERIVED PHARMACEUTICALS MARKET FOR ANTI-TUMOR, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 27. MARINE DERIVED PHARMACEUTICALS MARKET FOR ANTI-CARDIOVASCULAR, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 28. MARINE DERIVED PHARMACEUTICALS MARKET FOR ANTI-VIRAL, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 29. MARINE DERIVED PHARMACEUTICALS MARKET FOR ANTI-INFLAMMATORY, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 30. MARINE DERIVED PHARMACEUTICALS MARKET FOR OTHERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 31. MARINE DERIVED PHARMACEUTICALS MARKET SEGMENTATION, BY BY END USER
  • FIGURE 32. MARINE DERIVED PHARMACEUTICALS MARKET FOR HOSPITALS    , BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 33. MARINE DERIVED PHARMACEUTICALS MARKET FOR RETAIL PHARMACY, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 34. MARINE DERIVED PHARMACEUTICALS MARKET FOR ONLINE PHARMACY  , BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 35. MARINE DERIVED PHARMACEUTICALS MARKET FOR OTHERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 36. TOP WINNING STRATEGIES, BY YEAR, 2020-2022*
  • FIGURE 37. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2020-2022*
  • FIGURE 38. TOP WINNING STRATEGIES, BY COMPANY, 2020-2022*
  • FIGURE 39. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 40. COMPETITIVE DASHBOARD
  • FIGURE 41. COMPETITIVE HEATMAP: MARINE DERIVED PHARMACEUTICALS MARKET
  • FIGURE 42. Top player positioning, 2022
  • FIGURE 43. ABBOTT LABORATORIES: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 44. ABBOTT LABORATORIES: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 45. ABBOTT LABORATORIES: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 46. BAYER INNOVATION: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 47. BAYER INNOVATION: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 48. BAYER INNOVATION: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 49. MARINE POLYMER TECHNOLOGIES, INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 50. MARINE POLYMER TECHNOLOGIES, INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 51. MARINE POLYMER TECHNOLOGIES, INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 52. TAKEDA ONCOLOGY’S MILLENNIUM: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 53. TAKEDA ONCOLOGY’S MILLENNIUM: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 54. TAKEDA ONCOLOGY’S MILLENNIUM: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 55. GLAXOSMITHKLINE PLC: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 56. GLAXOSMITHKLINE PLC: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 57. GLAXOSMITHKLINE PLC: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 58. ABBVIE INC: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 59. ABBVIE INC: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 60. ABBVIE INC: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 61. AKER BIOMARINE AS: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 62. AKER BIOMARINE AS: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 63. AKER BIOMARINE AS: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 64. SEA RUN HOLDINGS, INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 65. SEA RUN HOLDINGS, INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 66. SEA RUN HOLDINGS, INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 67. APHIOS CORPORATION: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 68. APHIOS CORPORATION: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 69. APHIOS CORPORATION: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 70. SANOFI S.A.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 71. SANOFI S.A.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 72. SANOFI S.A.: REVENUE SHARE, BY REGION, 2032 (%)

 
 
With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

  • Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
  • Technologically sophisticated and reliable insights through well audited and veracious research methodology
  • Sovereign research proceeds that present a tangible depiction of marketplace


With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, web-casts and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast


Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develops analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth and forecasts


Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

  • Chief executives and VPs of leading corporations specific to industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)


Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : +44-845-528-1300
Email : help@alliedmarketresearch.com

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Enquiry Now
RELATED TAGS

Purchase Full Report of
Marine Derived Pharmaceuticals Market

Start reading.
This Report and over 67,068+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,690
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
  • Data Pack
  • $3,930
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Single User
  • $5,820
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Five Users
  • $6,540
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Enterprise
    License/PDF

  • $9,870
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Library
    Membership

  • $999 $ 1,175
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

RELATED REPORTS
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers